Ionis Pharmaceuticals' late-stage clinical trial of a cardiac drug failed, and the company's stock price fell 7%.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.